The results for the CD22/Siglec-2 probe are consistent with those we obtained in a previous study, which demonstrated similar degrees of terminal α2–6 sialylation of N-glycans in B cells from CLL patients and healthy donors (42). The gene discussed is CD22; the disease is B-cell chronic lymphocytic leukemia.